siRNA: A Comprehensive Review of Marketed Products till August 2022

References (52)

1. 1 Origins and Mechanisms of miRNAs and siRNAs [DOI]
2. 2 Human RISC Couples MicroRNA Biogenesis and Posttranscriptional Gene Silencing [DOI]
3. 3 MicroRNAs and other non-coding RNAs as targets for anticancer drug development [DOI]
4. 4 The current state and future directions of RNAi-based therapeutics [DOI]
5. 5 RNAi therapeutics: a potential new class of pharmaceutical drugs [DOI]
6. 6 siRNA Versus miRNA as Therapeutics for Gene Silencing [DOI]
7. 7 Non‐coding RNAs: regulators of disease [DOI]
8. 8 Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol [DOI]
9. 9 siRNA function in RNAi: A chemical modification analysis [DOI]
10. 10 Non-Coding RNAs and their Integrated Networks [DOI]
11. 11 Nanomedicine : nanotechnology, biology and medicine.
12. 12 Strategies, design, and chemistry in siRNA delivery systems [DOI]
13. 13 The Argonaute protein family [DOI]
14. 14 The Biogenesis and Function of PIWI Proteins and piRNAs: Progress and Prospect [DOI]
15. 15 Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1 [DOI]
16. 16 Molecular Mechanisms and Biological Functions of siRNA [DOI]
17. 17 The growth of siRNA-based therapeutics: Updated clinical studies [DOI]
18. 18 Current progress of siRNA/shRNA therapeutics in clinical trials [DOI]
19. 19 Cleavage of the siRNA passenger strand during RISC assembly in human cells [DOI]
20. 20 Therapeutic siRNA: State-of-the-Art and Future Perspectives [DOI]
21. 21 Uniting Germline and Stem Cells: The Function of Piwi Proteins and the piRNA Pathway in Diverse Organisms [DOI]
22. 22 Inclisiran: First Approval [DOI]
23. 23 Lumasiran: First Approval [DOI]
24. 24 Therapeutic siRNA: principles, challenges, and strategies.
25. 25 RNAi Mechanisms and Applications [DOI]
26. 26 RNAi and small interfering RNAs in human disease therapeutic applications [DOI]
27. 27 Coding or Noncoding, the Converging Concepts of RNAs [DOI]
28. 28 siRNA Specificity: RNAi Mechanisms and Strategies to Reduce Off-Target Effects [DOI]
29. 29 Acute Hepatic Porphyrias: Review and Recent Progress [DOI]
30. 30 siRNA Repositioning for Guide Strand Selection by Human Dicer Complexes [DOI]
31. 31 siRNA based drug design, quality, delivery and clinical translation [DOI]
32. 32 Argonaute Proteins: From Structure to Function in Development and Pathological Cell Fate Determination [DOI]
33. 33 Small non-coding RNAs mount a silent revolution in gene expression [DOI]
34. 34 Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9 [DOI]
35. 35 Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid, Givosiran, in Patients With Acute Hepatic Porphyria [DOI]
36. 36 Advances in the treatment of hereditary transthyretin amyloidosis: A review [DOI]
37. 37 Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review [DOI]
38. 38 siRNA therapeutics and its challenges: Recent advances in effective delivery for cancer therapy [DOI]
39. 39 Inclisiran: A Novel Agent for Lowering Apolipoprotein B–containing Lipoproteins [DOI]
40. 40 Coding and Non-coding RNAs, the Frontier Has Never Been So Blurred [DOI]
41. 41 Treatment of Transthyretin Amyloid Cardiomyopathy: The Current Options, the Future, and the Challenges [DOI]
42. 42 The Medicinal Chemistry of Artificial Nucleic Acids and Therapeutic Oligonucleotides [DOI]
43. 43 PIWI-Interacting RNAs (piRNAs): Promising Applications as Emerging Biomarkers for Digestive System Cancer [DOI]
44. 44 RNA Interference in Biology and Medicine [DOI]
45. 45 The therapeutic potential of siRNA in gene therapy of neurodegenerative disorders [DOI]
46. 46 Primary hyperoxaluria type 1: novel therapies at a glance [DOI]
47. 47 Lumasiran in the Management of Patients with Primary Hyperoxaluria Type 1: From Bench to Bedside [DOI]
48. 48 The microRNAs of Caenorhabditis elegans [DOI]
49. 49 Neuropsychiatric Disorders An Integrative Approach [DOI]
50. 50 Lumasiran: expanding the treatment options for patients with primary hyperoxaluria type 1 [DOI]
51. 51 Inclisiran creates unique opportunities and challenges for patient access to therapy: early experience in a United States Lipid Clinic [DOI]
52. 52 Orphan Drugs in Neurology—A Narrative Review [DOI]

Cited by 2

Showing 1 of 2 known citations — external sources report more than can currently be individually listed.

Related research

• Genetic Engineering in Insect Management: New Frontiers in Pest Control — shares topic coverage
• Validating 3-Phosphoinositide Dependent Protein Kinase-1 as a Drug Target in African Trypanosoma — shares topic coverage
• Current Strategies for Management of Plant Viruses and Future Perspectives: Enhancing Crop Health, Yield and Productivity — shares topic coverage
• Development of Tomato Leaf Curl Virus Resistance: From Plant Breeding to Genome Editing — shares topic coverage
• Biotechnological Initiative for Management of Mungbean Yellow Mosaic Virus in Mungbean (Vigna radiate L.) — shares topic coverage